Ryan Cawood, CSO at OXGENE and WuXi Advanced Therapies introduces TESSA – a ‘revolutionary’ technology for manufacturing AAV.
PLAY VIDEO ABOVE * OXGENE and Wuxi Advanced Therapies, the sponsor of this content would like to send you information about their products and services. If you do not wish to receive these emails, click here to opt out.
In this demo video, Ryan explains what TESSA technology – a novel, plasmid free approach to AAV manufacture – is and how it works. He introduces what effect TESSA-based AAV manufacture has on AAV yield and quality and outlines the benefit he sees this delivering to patients.
“TESSA can significantly reduce the costs of manufacturing AAV. The number of input reagents is significantly lower, the efficiency with which they’re delivered to the cells is significantly higher, and the productivity of the system is significantly higher as well.”